ArticleFrontiers in neurology
Exploration of the longitudinal clinical course and potential prognostic factors in Parkinson's disease: 2.5-year observational study in Japan.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several long-term studies have characterized the course of Parkinson's disease (PD) outside Japan, but few have been conducted in Japan. This study aimed to explore the longitudinal clinical course of PD symptoms in patients receiving standard therapy in Japan and to identify potential factors associated with clinically relevant worsening. Methods: This study used data from 348 patients with PD at Juntendo University Hospital, Japan. Baseline characteristics and longitudinal clinical status, including the Unified Parkinson's Disease Rating Scale (UPDRS) motor scores, were obtained and summarized. Factors potentially associated with clinically relevant worsening were also explored. Results: Among 194 analyzed patients, the study population predominantly had mild to moderate PD, with a mean age of 66.4 years, mean disease duration of 6.22 years, mean UPDRS III score of 20.0, and mean Hoehn and Yahr stage of 2.2. Most patients were receiving L-dopa (88.7%), with a mean daily dose of 477.0 mg. The mean UPDRS III score improved by 3.3 points at the 6-month visit and remained relatively stable for up to 2.5 years. In multivariate exploratory analyses, baseline motor severity, time from PD onset to referral, and orthostatic hypotension were associated with clinically relevant worsening. Conclusion: Our findings suggest that timely referral to specialized care and assessment of autonomic symptoms, particularly orthostatic hypotension, may help identify patients at higher risk of clinically relevant worsening in routine PD care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.